On the afternoon of March 30, 2022, at the AstraZeneca Chengdu headquarters of the Frontier Medical Center in Chengdu High-tech Zone, an exchange symposium with the theme of "deepening the integration of medicine and industry and promoting inclusive development" was launched in a friendly and warm atmosphere.
This exchange symposium was held to enhance the in-depth exchanges between the Medical Association and biopharmaceutical companies, expand the cooperation model, and hold the theme of how to deepen the integration of medicine and industry and promote inclusive development. Invited by AstraZeneca, Zeng Bin, Secretary-General of Chengdu High-tech Medical Association and Director of Medical-Industrial Integration Innovation Center; Ai He and Lin Fan, Deputy Secretary-General and Deputy Director of Medical-Industrial Integration Innovation Center; Bu Wei, Deputy Director of Medical-Industrial Integration Innovation Center ; Xin Juan, Minister of Academic Activities, and a group of 5 attended the meeting. AstraZeneca UGW South Xinxing Executive Director and Western General Manager Zhou Yike; Government Affairs Executive Director Huang Mei; Key Account Regional Deputy Director Gong Chunyan; iCampus Director Chen Kai; Medical Affairs Manager Deng Yumei; Key Account Regional Manager Liu Junfeng; iCampus Senior Manager Han Yuechen; Government Affairs Senior Manager Zhang Ting and Key Account Area Project Manager Tian Hong attended the meeting.
The secretariat of Chengdu High-tech Medical Association first visited the Chengdu Frontier Medical Center, which is the core content of the cooperation between Chengdu and Sichuan University. The innovation and development of basic research and clinical technology in medicine ("Medicine + New Engineering", "Medicine + Life Science") is committed to becoming a new core and source of innovation and development in Chengdu.
After the visit, the two sides held discussions on specific cooperation matters. At the meeting, Zeng Bin, Secretary-General of Chengdu High-tech Medical Association, firstly introduced the basic situation of Chengdu High-tech Medical Association. He emphasized that the society is committed to promoting medical innovation and medical-industrial integration, and is committed to providing full industry chain services for high-tech and biomedical research and development , to promote the recruitment of talents, the transformation of achievements and the implementation of industrial projects. This coincides with AstraZeneca's grand vision of "pioneering and innovating, benefiting patients, and becoming a trusted medical partner in China". This is also the basis for the society to cooperate with AstraZeneca dozens of times every year. It is hoped that this exchange meeting will achieve win-win cooperation, coordinated development, and promote information exchange, resource sharing, and complementary advantages between the two parties.
Zhou Yike, Executive Director of AstraZeneca UGW South Xinxing and General Manager of the Western Region, gave a company introduction. He said that AstraZeneca is an innovation-driven global biopharmaceutical company, focusing on the research and development, production and sales of prescription drugs for the medical industry. bring about profound changes. R&D and patients are at the forefront of AstraZeneca's work, focusing its strengths and resources on therapeutic areas where real and far-reaching changes can be made.
Chen Kai, Director of iCampus, introduced the AstraZeneca iCampus International Life Science Innovation Park. He said that the value proposition of iCampus is: linking the government, linking the industry, supporting experts, and gathering capital to empower and accelerate the innovation and development of AstraZeneca's therapeutic field. AstraZeneca supports the innovation and transformation of top experts to solve clinical pain points in the therapeutic field; cooperates with local governments to drive the industry and create innovative clusters in the therapeutic field. The company's work in 2022 will focus on deepening the ecosystem and accelerating innovation and development in the therapeutic field. Based on this, the cooperation between Chengdu High-tech Medical Association and AstraZeneca can be discussed as follows: regional medical transformation, in-hospital project cooperation, and early-stage project investment cooperation.
On how to deepen the integration of medicine and industry, promote inclusive development, build a platform for scientific and technological innovation, and promote the common development of both parties. In response to the exploration of cooperation between the two parties, Ai He, Deputy Secretary-General of Chengdu High-tech Medical Association, said:
First, the Medical Association can give full play to the characteristics of concentrated medical experts and strong resource advantages, and the two sides can jointly carry out in-depth medical-industrial cooperation;
The second is to carry out cooperation in clinical medical research projects focusing on the research and development of innovative drug candidates and proof-of-concept on the scientific and technological innovation platform of the Medical Association, and expand the integration channels;
The third is to carry out multi-level academic promotion cooperation through the academic exchange platform of the Medical Association;
The fourth is to give full play to AstraZeneca's business focus, which is also the in-depth promotion and application of products in the therapeutic areas most needed by patients.
Regarding the content of cooperation between the two parties, Zeng Bin, Secretary-General of Chengdu High-tech Medical Association, further emphasized that the principle of cooperation is to link the government, link industries, support experts, gather capital, and promote innovation and development in the field of treatment. He pointed out that the content of cooperation can be further expanded to:
The first is to learn to cooperate with your company in early and mid-term projects incubated;
Second, homogeneous and low-cost clinical multi-center scientific research cooperation;
The third is product popularization and market warm-up before listing;
Fourth, post-marketing product academic promotion and extensive clinical adverse reactions research.
The visit strengthened the exchanges and cooperation between AstraZeneca and Chengdu High-tech Medical Association. In 2022, the two parties will be committed to serving the health of the western region, promoting the development of traditional Chinese medicine in the western region, jointly building a new model of an integrated medical ecosystem, striving for the realization of more innovative management and innovative medical solutions, and continuously meeting the needs of western medical development and benefiting The vast number of patients in the west work hand in hand.
With the in-depth integration of medicine and industry, China's smart medical system has been formed and with the rapid development of globalization, it will change China's medical service model in the future, deepen the integration of medicine and industry, make treatment more accurate, and promote traditional medical care to smart medical care. Transformation will be our responsibility and mission. "Deepen the integration of medicine and industry, and promote the development of inclusiveness", constantly share the latest achievements and applications of the integration of medicine and industry, and contribute to the implementation of the national strategy of "Healthy China" and the construction of Chengdu High-tech Zone into a world-class science and technology industrial park.
